Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2024-09-27
2044-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Patients With HER2-Positive Metastatic Breast Cancer
NCT00105456
microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin
NCT02656589
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
NCT03460067
Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer
NCT06358625
Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype
NCT06813456
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HER2-positive breast cancer
Patients with stage I-IV HER2-positive breast cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Priyanka Sharma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Priyanka Sharma
Professor of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KUCC - Indian Creek
Overland Park, Kansas, United States
KUCC - Overland Park
Overland Park, Kansas, United States
KUCC - Briarcliff
Westwood, Kansas, United States
KUCC - Olathe
Westwood, Kansas, United States
The University of Kansas Cancer Center
Westwood, Kansas, United States
KUCC - Lee's Summit
Lee's Summit, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
160944
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.